Skip to main content

Mitochondrial Dynamics as a Therapeutic Target for Treating Cardiac Diseases

  • Chapter
  • First Online:
Pharmacology of Mitochondria

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 240))

Abstract

Mitochondria are dynamic in nature and are able to shift their morphology between elongated interconnected mitochondrial networks and a fragmented disconnected arrangement by the processes of mitochondrial fusion and fission, respectively. Changes in mitochondrial morphology are regulated by the mitochondrial fusion proteins – mitofusins 1 and 2 (Mfn1 and 2), and optic atrophy 1 (Opa1) as well as the mitochondrial fission proteins – dynamin-related peptide 1 (Drp1) and fission protein 1 (Fis1). Despite having a unique spatial arrangement, cardiac mitochondria have been implicated in a variety of disorders including ischemia–reperfusion injury (IRI), heart failure, diabetes, and pulmonary hypertension. In this chapter, we review the influence of mitochondrial dynamics in these cardiac disorders as well as their potential as therapeutic targets in tackling cardiovascular disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

Akt:

Protein kinase B (PKB)

ANT:

Adenine nucleotide translocator

APOO:

Apolipoprotein O

ATP:

Adenosine triphosphate

Ca2+ :

Calcium ions

CsA:

Cyclosporine A

Cx-43:

Connexin-43

CypD:

Cyclophilin D

Drp1:

Dynamin-related peptide 1

ER:

Endoplasmic reticulum

ETC:

Electron transport chain

FATP1:

Fatty acid transport protein 1

Grp75:

Glucose-regulated protein 75

GTPases:

Guanosine triphosphatases

HKII:

Hexokinase II

H2O2 :

Hydrogen peroxide

IF:

Interfibrillar

IMM:

Inner mitochondrial membrane

IP3R:

Inositol 1,4,5-triphosphate receptor

IR:

Ischemia–reperfusion

IRI:

Ischemia–reperfusion injury

KCl:

Potassium chloride

LV:

Left ventricle

MARF:

Mitochondrial assembly regulatory factor

Mdivi-1:

Mitochondrial division inhibitor 1

Mff:

Mitochondrial fission factor

Mfn1:

Mitofusin 1

Mfn2:

Mitofusin 2

MI:

Myocardial infarct

MiD49/51:

Mitochondrial dynamics proteins of 49 and 51 kDa

MLKL:

Mixed lineage kinase domain like protein

MMP:

Mitochondrial membrane potential

MOMP:

Mitochondrial outer membrane permeabilization

mPTP:

Mitochondrial permeability transition pore

mTOR:

Mechanistic target of rapamycin

OMM:

Outer mitochondrial membrane

Opa1:

Optic atrophy 1

OPA1-KD:

OPA1-knockdown

PAH:

Pulmonary arterial hypertension

pAkt:

Phospho-Akt

PASMC:

Pulmonary artery smooth muscle cell

PERK:

Protein kinase RNA-like endoplasmic reticulum kinase

PGC-1α:

PPAR gamma coactivator-1

PiC:

Inorganic phosphate carrier

PPAR:

Peroxisome proliferator-activated receptor

RIP:

Receptor-interacting protein

ROS:

Reactive oxygen species

SENP3:

SUMO1/sentrin/SMT3 specific peptidase 3

sI:

Simulated ischemia

sIRI:

Simulated ischemia–reperfusion injury

siRNA:

Small interfering RNA

Smac/DIABLO:

Second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI

SSC:

Subsarcolemmal

SUMOs:

Small ubiquitin-like modifiers

TNF-α:

Tumor necrosis factor alpha

UPR:

Unfolded protein response

VDAC:

Voltage-dependent anion channel

References

Download references

Acknowledgements

Sang-Bing Ong is supported by the Singapore Ministry of Health’s National Medical Research Council under its Open Fund—Young Individual Research Grant (OF-YIRG) scheme and a Khoo Postdoctoral Fellowship Award (KPFA) from the Estate of Tan Sri Khoo Teck Puat, Singapore. Derek John Hausenloy was supported by the British Heart Foundation (FS/10/039/28270), the Rosetrees Trust, and the National Institute for Health Research University College London Hospitals Biomedical Research Centre.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sang-Bing Ong .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Ong, SB., Hausenloy, D.J. (2016). Mitochondrial Dynamics as a Therapeutic Target for Treating Cardiac Diseases. In: Singh, H., Sheu, SS. (eds) Pharmacology of Mitochondria. Handbook of Experimental Pharmacology, vol 240. Springer, Cham. https://doi.org/10.1007/164_2016_7

Download citation

Publish with us

Policies and ethics